| XLS |
|
|
|
| ||
|
€ million |
Q1 – 2013 |
Q1 – 2012 | ||
| ||||
|
Sales |
2,660.4 |
2,563.9 | ||
|
Royalty, license and commission income |
100.1 |
81.1 | ||
|
Total revenues |
2,760.5 |
2,644.9 | ||
|
|
|
| ||
|
Cost of sales |
–724.0 |
–748.7 | ||
|
Gross profit |
2,036.5 |
1,896.2 | ||
|
|
|
| ||
|
Marketing and selling expenses |
–568.3 |
–586.6 | ||
|
Royalty, license and commission expenses |
–136.3 |
–120.0 | ||
|
Administration expenses |
–132.7 |
–136.41 | ||
|
Other operating expenses and income |
–184.0 |
–144.6 | ||
|
Research and development |
–406.2 |
–381.8 | ||
|
Amortization of intangible assets |
–209.6 |
–216.3 | ||
|
Investment result |
– |
– | ||
|
Operating result (EBIT) |
399.4 |
310.61 | ||
|
|
|
| ||
|
Financial result |
–58.7 |
–66.11 | ||
|
Profit before income tax |
340.7 |
244.51 | ||
|
|
|
| ||
|
Income tax |
–71.7 |
–69.4 | ||
|
Profit after tax |
269.0 |
175.11 | ||
|
|
|
| ||
|
of which attributable to Merck KGaA shareholders (net income) |
266.0 |
172.71 | ||
|
of which attributable to non-controlling interest |
3.0 |
2.4 | ||
|
|
|
| ||
|
Earnings per share (in €) |
|
| ||
|
basic |
1.22 |
0.791 | ||
|
diluted |
1.22 |
0.791 | ||